Freestone Grove Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Freestone Grove Partners’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,404	Closed	-$1.37M	–	886
2025 Q1	$1.37M	Buy	+10,404	New	+$1.3M	0.01%	326

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Freestone Grove Partners's ITCI Position: Q2 2025 in Review

Freestone Grove Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 10,404 shares — an estimated $1.37M sold.

Freestone Grove Partners first reported a position in ITCI in Q1 2025 and held it in 1 quarter. The position peaked at $1.37M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Freestone Grove Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Freestone Grove Partners sold 10,404 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $1.37M.
Freestone Grove Partners first reported a position in Intra-Cellular Therapies Inc. in Q1 2025 and held it in 1 quarter.
Freestone Grove Partners's Intra-Cellular Therapies Inc. position peaked at $1.37M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Freestone Grove Partners's 13F filing for Q2 2025, filed 14 Aug 2025.